Mereo BioPharma Group plc

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations ($29.5m) ($43.3m) ($41.9m) ($35.7m)
Depreciation $171k $143k $157k $698k
Amortization of Intangible Assets $395k $438k $465k
Depreciation of property, plant and equipment $36k $39k $1.6m $1.6m $642k $727k $1.2m
Amortization Cash Flow $395k $438k $465k
Amortization Of Intangibles $395k $438k $465k $486k
Depreciation Amortization Depletion $1.1m $1.1m $1.1m $1.2m
Deferred Income Tax Expense (Benefit) ($5.3m) ($8.2m) ($1.1m) ($10.4m) ($2.8m) $1.5m $0 $0
Share-based Payment Arrangement, Noncash Expense $4.9m $7.4m $7.6m $6.9m
Adjustments For Share-Based Payments $3.7m $2.2m $1.6m $1.6m $3.3m $3.9m
Share-based payments expense $3.7m $2.2m $1.6m $1.6m $3.3m $3.9m
Other Nonoperating Income (Expense) ($10k) $0 $300k
Changes in operating assets and liabilities:
Change In Working Capital ($1.6m) ($369k) ($3.2m) ($528k)
Decrease/(increase) in receivables and prepayments ($840k) $804k ($936k) $141k ($589k) $695k
Change In Receivables $456k ($1.6m) $1.4m $349k
Increase (Decrease) in Accounts Payable ($1.3m) $146k ($1.4m) $217k
Increase/(decrease) in trade and other payables and accruals $3.9m $1.6m ($6.7m) ($3.6m) ($1.3m) $1.1m
Change In Payables And Accrued Expense ($2.0m) ($1.0m) ($3.8m) $217k
Change In Accrued Expense ($710k) ($1.2m) ($2.4m) ($775k)
Increase in provisions and other liabilities ($1.0m) ($517k) $162k $1.4m $211k
Change In Other Current Liabilities ($578k) ($654k) ($743k) ($774k)
Net Cash Provided by (Used in) Operating Activities ($32.1m)
($23.1m) +28.03%
($45.9m) -98.50%
($28.3m) +38.30%
($5.2m) +81.51%
($38.8m) -640.98%
($21.1m) +45.56%
($32.8m) -55.38%
($31.0m) +5.67%
($27.0m) +12.97%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($16k) ($36k) ($21k) ($16k) ($535k) ($10k) $0 ($699k) $20k ($300k)
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities $2k
Net Other Investing Changes ($814k) $300k $300k
Net cash flows (used in)/from investing activities ($3.7m) $252k $43.3m $1.5m ($421k) $1.5m
Net Cash Provided by (Used in) Investing Activities ($419k) ($699k) ($20k) $0
Cash flows from financing activities:
Gain (Loss) on Extinguishment of Debt $0
Proceeds From Borrowings Classified As Financing Activities $20.0m $455k $44.4m
Repayments Of Borrowings Classified As Financing Activities $19.8m
Transaction costs relates to loans and borrowings ($921k) $0 ($81k)
Issuance Of Debt $0 $0 $0
Long Term Debt Issuance $0 $0 $0
Net Issuance Payments Of Debt ($934k) ($1.1m) ($3.2m) $0 $0
Net Long Term Debt Issuance ($934k) ($1.1m) ($3.2m) $0 $0
Long Term Debt Payments ($934k) ($1.1m) ($3.2m) $0 $0
Repayment Of Debt ($934k) ($1.1m) ($3.2m) $0 $0
Issuance Of Capital Stock $0 $11.6m $47.0m $39k $39k
Proceeds from Issuance of Common Stock $11.6m $47.0m $39k $39k
Common Stock Issuance $0 $11.6m $47.0m $39k $39k
Cash Dividends Paid $0 $0 $0
Net Other Financing Charges ($444k) ($853k) ($199k) ($199k)
Net cash flows (used in)/from financing activities $33.7m
($2.1m) -106.15%
($5.7m) -175.18%
$34.7m +708.35%
$77.7m +123.54%
($784k) -101.01%
Net Cash Provided by (Used in) Financing Activities $8.0m
$46.1m +478.79%
$327k -99.29%
($95k) -129.05%
Net (decrease)/increase in cash and cash equivalents ($2.1m) ($25.0m) ($8.3m) $7.9m $72.0m ($38.1m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $12.4m $35.4m
Beginning Cash Position $68.2m $57.4m $69.8m $62.5m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.8m ($233k) $1.9m $789k
Effect of exchange rate changes ($1.4m) ($41k) ($349k) $253k ($1.2m) $145k $2.8m ($233k) $1.9m $789k
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Income Tax Expense (Benefit) ($532k) $0 $0
Additional Financial Items
Adjustments For Decrease Increase In Trade Account Receivable ($840k) $804k
Adjustments For Finance Costs $1.1m $1.9m $3.7m $6.2m $3.8m $2.9m
Adjustments For Increase Decrease In Trade Account Payable $3.9m $1.6m
Adjustments For Unrealised Foreign Exchange Losses Gains $1.4m $44k ($483k) $1.8m $954k ($2.1m)
Foreign Currency Transaction Gain (Loss), before Tax ($2.3m) $1.2m ($6.3m)
General and Administrative Expense $18.4m $26.4m $23.0m
Interest Received Classified As Operating Activities ($827k) ($307k)
Investment Income, Interest $2.1m $3.0m $2.2m
Operating Costs and Expenses $700k $700k $700k
Payments Of Lease Liabilities Classified As Financing Activities $2.2m $2.1m $692k $937k
Payments To Acquire Or Redeem Entitys Shares $307k $998k
Proceeds From Issuing Shares $15.0m $273k $20.1m $78.5m
Purchase Of Intangible Assets Classified As Investing Activities $2.3m
(Loss)/profit before tax ($47.0m) ($37.3m) ($41.1m) ($166.4m) $14.2m ($36.1m)
Net foreign exchange (gain)/loss $1.4m $44k ($483k) $1.8m $954k ($2.1m)
Finance income ($307k) ($377k) ($44k) ($1k) ($696k)
Finance costs $1.1m $1.9m $3.7m $6.2m $3.8m $2.9m
Other non-cash movements $156k $647k
Fair value remeasurement on warrants ($716k) ($875k) $109.8m ($40.0m) ($7.8m)
(Gain)/loss on disposal of intangible assets $10.9m ($113k)
Taxation $5.3m $8.2m $1.1m $10.4m $2.8m ($1.5m)
Acquisition of subsidiary $10.1m ($354k)
Proceeds from intangible assets (net of transaction costs) $1.8m $113k $1.5m
Interest earned $1.1m $286k $377k $44k $1k $696k
Proceeds from issuance of ordinary shares $15.0m $273k $0 $20.1m $78.5m
Transaction costs on issuance of shares ($730k) ($8k) ($761k) ($1.3m) ($234k)
Proceeds from exercise of employee share options $0 $46k
Transaction costs on issuance of convertible loan notes ($200k) ($921k) ($3.6m)
[Proceeds from TAP agreement] $78k $153k
Payment of lease liabilities ($2.2m) ($2.1m) ($692k) ($937k)
Cash Flow From Continuing Financing Activities $8.0m $46.1m $327k ($95k)
Cash Flow From Continuing Investing Activities ($419k) ($699k) ($20k) $0
Change In Account Payable ($1.3m) $146k ($1.4m) $217k
Change In Payable ($1.3m) $146k ($1.4m) $217k
Change In Prepaid Assets $502k $3.0m ($84k) $455k
Changes In Cash ($13.6m) $12.6m ($30.7m) ($27.0m)
End Cash Position $57.4m $69.8m $41.0m $35.4m
Financing Cash Flow $8.0m
$46.1m +478.79%
$327k -99.29%
($95k) -129.05%
Free Cash Flow ($21.6m) ($33.5m) ($31.3m) ($27.3m)
Gain Loss On Investment Securities ($245k) $419k ($909k) ($510k)
Gain Loss On Sale Of PPE ($153k) $0 $0
Interest Received CFI $1k $842k $991k
Investing Cash Flow ($419k) ($699k) ($20k) $0
Net Business Purchase And Sale $0 $0 $0
Net Foreign Currency Exchange Gain Loss $2.3m ($1.2m) $6.3m $2.0m
Net Intangibles Purchase And Sale ($419k) ($699k) ($300k) ($300k)
Net PPE Purchase And Sale $0 $0 ($20k) $0
Operating Gains Losses $2.1m ($791k) $5.4m $1.4m
Other Non Cash Items $1.8m $3.1m ($72k)
Proceeds From Stock Option Exercised $62k $0 $0 $487k $0
Provisionand Write Offof Assets $1.9m $255k $1.0m
Purchase Of Business $0 $0 $0
Purchase Of Intangibles ($419k) ($699k) ($300k) ($300k)
Purchase Of PPE $0 $0 ($20k) ($300k)
Sale Of Intangibles $153k $1.8m $0
Stock Based Compensation $4.9m $7.4m $7.6m $6.9m
Gain (Loss) on Derivative Instruments, Net, Pretax $245k ($419k) $805k
Cash and cash equivalents at January 1 $50.0m $25.0m $16.3m $23.5m $94.3m $56.3m
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported ($10.8m) $12.6m ($30.7m)
Interest Paid, Excluding Capitalized Interest, Operating Activities ($327k) ($1.6m) ($1.7m) ($2.9m) $0 $0 $884k $21k $29k
Interest Paid Classified As Financing Activities $327k $1.6m $1.7m $2.9m $0 $0
Income Taxes Paid, Net ($1.3m) $0